TY - JOUR
T1 - A unified simulation model for understanding the diversity of cancer evolution
AU - Niida, Atsushi
AU - Hasegawa, Takanori
AU - Innan, Hideki
AU - Shibata, Tatsuhiro
AU - Mimori, Koshi
AU - Miyano, Satoru
N1 - Funding Information:
This research was supported by AMED under Grant Number JP17cm0106504h0002; MEXT as Priority Issue on Post-K computer (Supercomputer Fugaku) (Project ID: hp170227); and JSPS as Grant-in-Aid for Scientific Research on Innovative Areas (15H0912) and Grant-in-Aid for Scientific Research (JP15H05707 and JP19K08123). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Funding Information:
The following grant information was disclosed by the authors: AMED: JP17cm0106504h0002. MEXT as Priority Issue on Post-K computer (Supercomputer Fugaku): hp170227. JSPS as Grant-in-Aid for Scientific Research on Innovative Areas: 15H0912. Grant-in-Aid for Scientific Research: JP15H05707, JP19K08123.
Funding Information:
This research was supported by AME Dunder Grant Number JP17cm0106504h0002; MEXT as Priority Issue on Post-K computer (Supercomputer Fugaku) (Project ID: hp170227); and JSPS as Grant-in-Aid for Scientific Research on Innovative Areas (15H0912) and Grant-in-Aid for Scientific Research (JP15H05707 and JP19K08123). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Publisher Copyright:
© 2020 Journal of Global Pharma Technology. All rights reserved.
PY - 2020
Y1 - 2020
N2 - Because cancer evolution underlies the therapeutic difficulties of cancer, it is clinically important to understand the evolutionary dynamics of cancer. Thus far, a number of evolutionary processes have been proposed to be working in cancer evolution. However, there exists no simulation model that can describe the different evolutionary processes in a unified manner. In this study, we constructed a unified simulation model for describing the different evolutionary processes and performed sensitivity analysis on the model to determine the conditions in which cancer growth is driven by each of the different evolutionary processes. Our sensitivity analysis has successfully provided a series of novel insights into the evolutionary dynamics of cancer. For example, we found that, while a high neutral mutation rate shapes neutral intratumor heterogeneity (ITH) characterized by a fractal-like pattern, a stem cell hierarchy can also contribute to shaping neutral ITH by apparently increasing the mutation rate. Although It has been reported that the evolutionary principle shaping ITH shifts from selection to accumulation of neutral mutations during colorectal tumorigenesis, our simulation revealed the possibility that this evolutionary shift is triggered by drastic evolutionary events that occur in a short time and confer a marked fitness increase on one or a few cells. This result helps us understand that each process works not separately but simultaneously and continuously as a series of phases of cancer evolution. Collectively, this study serves as a basis to understand in greater depth the diversity of cancer evolution.
AB - Because cancer evolution underlies the therapeutic difficulties of cancer, it is clinically important to understand the evolutionary dynamics of cancer. Thus far, a number of evolutionary processes have been proposed to be working in cancer evolution. However, there exists no simulation model that can describe the different evolutionary processes in a unified manner. In this study, we constructed a unified simulation model for describing the different evolutionary processes and performed sensitivity analysis on the model to determine the conditions in which cancer growth is driven by each of the different evolutionary processes. Our sensitivity analysis has successfully provided a series of novel insights into the evolutionary dynamics of cancer. For example, we found that, while a high neutral mutation rate shapes neutral intratumor heterogeneity (ITH) characterized by a fractal-like pattern, a stem cell hierarchy can also contribute to shaping neutral ITH by apparently increasing the mutation rate. Although It has been reported that the evolutionary principle shaping ITH shifts from selection to accumulation of neutral mutations during colorectal tumorigenesis, our simulation revealed the possibility that this evolutionary shift is triggered by drastic evolutionary events that occur in a short time and confer a marked fitness increase on one or a few cells. This result helps us understand that each process works not separately but simultaneously and continuously as a series of phases of cancer evolution. Collectively, this study serves as a basis to understand in greater depth the diversity of cancer evolution.
UR - http://www.scopus.com/inward/record.url?scp=85083674610&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85083674610&partnerID=8YFLogxK
U2 - 10.7717/peerj.8842
DO - 10.7717/peerj.8842
M3 - Article
AN - SCOPUS:85083674610
SN - 2167-8359
VL - 2020
JO - PeerJ
JF - PeerJ
IS - 4
M1 - 8842
ER -